Table 2.
Vaccine efficacy against first or only episode of herpes zoster in ZOE-50/70 participants reporting at least 1 of the 15 selected medical conditions at enrollment (pooled modified Total Vaccinated Cohort).
| RZV |
Placebo |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| N | n | Cumulative follow-uppy | Rate of HZ cases/ 1,000 py |
N | n | Cumulative follow-up py |
Rate of HZ cases/ 1,000 py |
Vaccine efficacy % (95% CI) |
|
| Selected medical conditions present at enrollment | |||||||||
| Hypertension | 7,206 | 21 | 27,202.9 | 0.8 | 7,226 | 254 | 26,752.4 | 9.5 | 91.9 (87.3–95.1) |
| Osteoarthritis and/or vertebral disorders | 4,951 | 16 | 18,732.8 | 0.9 | 5,032 | 178 | 18,604.4 | 9.6 | 91.1 (85.1–95.0) |
| Dyslipidemia | 4,628 | 15 | 17578.0 | 0.9 | 4,707 | 169 | 17,507.2 | 9.7 | 91.2 (85.1–95.2) |
| Diabetes | 2,350 | 7 | 8,723.8 | 0.8 | 2,372 | 80 | 8,652.7 | 9.2 | 91.2 (81.1–96.6) |
| Osteoporosis/Osteopenia | 1,481 | 5 | 5,551.7 | 0.9 | 1,528 | 72 | 5,552.1 | 13.0 | 92.9 (82.7–97.8) |
| Gastroesophageal reflux disease | 1,334 | 6 | 5,009.7 | 1.2 | 1,313 | 44 | 4,816.2 | 9.1 | 86.9 (69.0–95.4) |
| Sleep disorder | 1,304 | 4 | 4,899.3 | 0.8 | 1,309 | 56 | 4,803.3 | 11.7 | 93.1 (81.4–98.2) |
| Prostatic diseases | 1,244 | 2 | 4,648.4 | 0.4 | 1,285 | 50 | 4,667.0 | 10.7 | 96.1 (85.1–99.5) |
| Hypothyroidism | 1,167 | 4 | 4,387.0 | 0.9 | 1,147 | 28 | 4,241.0 | 6.6 | 86.2 (60.4–96.5) |
| Depression | 1,017 | 2 | 3,767.1 | 0.5 | 987 | 29 | 3,567.5 | 8.1 | 93.4 (74.1–99.2) |
| Coronary heart disease | 1,003 | 1 | 3,773.8 | 0.3 | 1,055 | 35 | 3,912.8 | 8.9 | 97.0 (82.3–99.9) |
| Cataract | 782 | 4 | 2,964.7 | 1.3 | 800 | 41 | 2,931.0 | 14.0 | 90.4 (73.4–97.5) |
| Asthma | 646 | 3 | 2,420.9 | 1.2 | 689 | 28 | 2,575.8 | 10.9 | 88.8 (63.6–97.8) |
| Respiratory disorders# | 614 | 3 | 2,220.5 | 1.4 | 560 | 17 | 1,944.4 | 8.7 | 84.5 (46.4–97.1) |
| Renal disorders | 308 | 1 | 1,064.8 | 0.9 | 300 | 7 | 1,001.5 | 7.0 | 86.6 (-4.5–99.7) |
| Number of selected medical conditions present at enrollment | |||||||||
| 1 | 3,159 | 5 | 12,269.2 | 0.4 | 3,211 | 109 | 12,213.4 | 8.9 | 95.4 (89.0–98.5) |
| 2 | 3,080 | 7 | 11,797.1 | 0.6 | 3,117 | 97 | 11,746.4 | 8.3 | 92.8 (84.7–97.2) |
| 3 | 2,316 | 8 | 8,803.7 | 0.9 | 2,455 | 88 | 9,162.6 | 9.6 | 90.5 (80.5–96.0) |
| At least 3 | 5,188 | 19 | 19,417.0 | 1.0 | 5,280 | 199 | 19,338.4 | 10.3 | 90.5 (84.8–94.4) |
| At least 4 | 2,872 | 11 | 10,613.3 | 1.0 | 2,825 | 111 | 10,175.8 | 10.9 | 90.6 (82.4–95.4) |
| At least 5 | 1,406 | 5 | 5,132.5 | 1.0 | 1,350 | 52 | 4,742.4 | 11.0 | 91.2 (78.0–97.3) |
| At least 6 | 569 | 2 | 2,039.2 | 1.0 | 551 | 20 | 1,910.1 | 10.5 | 90.9 (62.5–99.0) |
RZV = participants receiving the adjuvanted recombinant zoster vaccine; Placebo = participants receiving placebo; ZOE-50/70 = RZV efficacy studies in adults ≥50 YOA (NCT01165177) and ≥70 YOA (NCT01165229), respectively; N = number of participants in each category; n = number of confirmed first or only herpes zoster case; HZ, herpes zoster; CI = confidence interval; py = person years. The follow-up period was censored at the first occurrence of a confirmed HZ episode.
#Other than asthma.